Once-soaring Peregrine plunges 78.5% on Phase IIb bavituximab 'discrepancies'
This article was originally published in Scrip
Peregrine Pharmaceuticals plunged 78.5% on the Nasdaq when its stock fell from $5.39 to $1.16 per share on 24 September after the company said investors should not rely on impressive Phase IIb overall survival (OS) data reported earlier in the month for bavituximab in the treatment of non-small-cell lung cancer (NSCLC) due to "major discrepancies" in information provided by a third-party vendor.
You may also be interested in...
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.